Global and Japan Influenzavirus B Infection Drug Market Insights, Forecast to 2026
SKU ID : QYR-16433121 | Publishing Date : 16-Sep-2020 | No. of pages : 177
Detailed TOC of Global and Japan Influenzavirus B Infection Drug Market Insights, Forecast to 2026
1 Study Coverage1.1 Influenzavirus B Infection Drug Product Introduction
1.2 Market Segments
1.3 Key Influenzavirus B Infection Drug Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Influenzavirus B Infection Drug Market Size Growth Rate by Type
1.4.2 APP-309
1.4.3 CF-403
1.4.4 GC-3106A
1.4.5 KIN-1400
1.4.6 Others
1.5 Market by Application
1.5.1 Global Influenzavirus B Infection Drug Market Size Growth Rate by Application
1.5.2 Clinic
1.5.3 Hospital
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Influenzavirus B Infection Drug Market Size, Estimates and Forecasts
2.1.1 Global Influenzavirus B Infection Drug Revenue 2015-2026
2.1.2 Global Influenzavirus B Infection Drug Sales 2015-2026
2.2 Global Influenzavirus B Infection Drug, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.3 Influenzavirus B Infection Drug Historical Market Size by Region (2015-2020)
2.3.1 Global Influenzavirus B Infection Drug Retrospective Market Scenario in Sales by Region: 2015-2020
2.3.2 Global Influenzavirus B Infection Drug Retrospective Market Scenario in Revenue by Region: 2015-2020
2.4 Influenzavirus B Infection Drug Market Estimates and Projections by Region (2021-2026)
2.4.1 Global Influenzavirus B Infection Drug Sales Forecast by Region (2021-2026)
2.4.2 Global Influenzavirus B Infection Drug Revenue Forecast by Region (2021-2026)
3 Global Influenzavirus B Infection Drug Competitor Landscape by Players
3.1 Global Top Influenzavirus B Infection Drug Sales by Manufacturers
3.1.1 Global Influenzavirus B Infection Drug Sales by Manufacturers (2015-2020)
3.1.2 Global Influenzavirus B Infection Drug Sales Market Share by Manufacturers (2015-2020)
3.2 Global Influenzavirus B Infection Drug Manufacturers by Revenue
3.2.1 Global Influenzavirus B Infection Drug Revenue by Manufacturers (2015-2020)
3.2.2 Global Influenzavirus B Infection Drug Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Influenzavirus B Infection Drug Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Influenzavirus B Infection Drug Revenue in 2019
3.2.5 Global Influenzavirus B Infection Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Global Influenzavirus B Infection Drug Price by Manufacturers
3.4 Global Influenzavirus B Infection Drug Manufacturing Base Distribution, Product Types
3.4.1 Influenzavirus B Infection Drug Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Influenzavirus B Infection Drug Product Type
3.4.3 Date of International Manufacturers Enter into Influenzavirus B Infection Drug Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Influenzavirus B Infection Drug Market Size by Type (2015-2020)
4.1.1 Global Influenzavirus B Infection Drug Sales by Type (2015-2020)
4.1.2 Global Influenzavirus B Infection Drug Revenue by Type (2015-2020)
4.1.3 Influenzavirus B Infection Drug Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Influenzavirus B Infection Drug Market Size Forecast by Type (2021-2026)
4.2.1 Global Influenzavirus B Infection Drug Sales Forecast by Type (2021-2026)
4.2.2 Global Influenzavirus B Infection Drug Revenue Forecast by Type (2021-2026)
4.2.3 Influenzavirus B Infection Drug Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Influenzavirus B Infection Drug Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global Influenzavirus B Infection Drug Market Size by Application (2015-2020)
5.1.1 Global Influenzavirus B Infection Drug Sales by Application (2015-2020)
5.1.2 Global Influenzavirus B Infection Drug Revenue by Application (2015-2020)
5.1.3 Influenzavirus B Infection Drug Price by Application (2015-2020)
5.2 Influenzavirus B Infection Drug Market Size Forecast by Application (2021-2026)
5.2.1 Global Influenzavirus B Infection Drug Sales Forecast by Application (2021-2026)
5.2.2 Global Influenzavirus B Infection Drug Revenue Forecast by Application (2021-2026)
5.2.3 Global Influenzavirus B Infection Drug Price Forecast by Application (2021-2026)
6 Japan by Players, Type and Application
6.1 Japan Influenzavirus B Infection Drug Market Size YoY Growth 2015-2026
6.1.1 Japan Influenzavirus B Infection Drug Sales YoY Growth 2015-2026
6.1.2 Japan Influenzavirus B Infection Drug Revenue YoY Growth 2015-2026
6.1.3 Japan Influenzavirus B Infection Drug Market Share in Global Market 2015-2026
6.2 Japan Influenzavirus B Infection Drug Market Size by Players (International and Local Players)
6.2.1 Japan Top Influenzavirus B Infection Drug Players by Sales (2015-2020)
6.2.2 Japan Top Influenzavirus B Infection Drug Players by Revenue (2015-2020)
6.3 Japan Influenzavirus B Infection Drug Historic Market Review by Type (2015-2020)
6.3.1 Japan Influenzavirus B Infection Drug Sales Market Share by Type (2015-2020)
6.3.2 Japan Influenzavirus B Infection Drug Revenue Market Share by Type (2015-2020)
6.3.3 Japan Influenzavirus B Infection Drug Price by Type (2015-2020)
6.4 Japan Influenzavirus B Infection Drug Market Estimates and Forecasts by Type (2021-2026)
6.4.1 Japan Influenzavirus B Infection Drug Sales Forecast by Type (2021-2026)
6.4.2 Japan Influenzavirus B Infection Drug Revenue Forecast by Type (2021-2026)
6.4.3 Japan Influenzavirus B Infection Drug Price Forecast by Type (2021-2026)
6.5 Japan Influenzavirus B Infection Drug Historic Market Review by Application (2015-2020)
6.5.1 Japan Influenzavirus B Infection Drug Sales Market Share by Application (2015-2020)
6.5.2 Japan Influenzavirus B Infection Drug Revenue Market Share by Application (2015-2020)
6.5.3 Japan Influenzavirus B Infection Drug Price by Application (2015-2020)
6.6 Japan Influenzavirus B Infection Drug Market Estimates and Forecasts by Application (2021-2026)
6.6.1 Japan Influenzavirus B Infection Drug Sales Forecast by Application (2021-2026)
6.6.2 Japan Influenzavirus B Infection Drug Revenue Forecast by Application (2021-2026)
6.6.3 Japan Influenzavirus B Infection Drug Price Forecast by Application (2021-2026)
7 North America
7.1 North America Influenzavirus B Infection Drug Market Size YoY Growth 2015-2026
7.2 North America Influenzavirus B Infection Drug Market Facts & Figures by Country
7.2.1 North America Influenzavirus B Infection Drug Sales by Country (2015-2020)
7.2.2 North America Influenzavirus B Infection Drug Revenue by Country (2015-2020)
7.2.3 U.S.
7.2.4 Canada
8 Europe
8.1 Europe Influenzavirus B Infection Drug Market Size YoY Growth 2015-2026
8.2 Europe Influenzavirus B Infection Drug Market Facts & Figures by Country
8.2.1 Europe Influenzavirus B Infection Drug Sales by Country
8.2.2 Europe Influenzavirus B Infection Drug Revenue by Country
8.2.3 Germany
8.2.4 France
8.2.5 U.K.
8.2.6 Italy
8.2.7 Russia
9 Asia Pacific
9.1 Asia Pacific Influenzavirus B Infection Drug Market Size YoY Growth 2015-2026
9.2 Asia Pacific Influenzavirus B Infection Drug Market Facts & Figures by Country
9.2.1 Asia Pacific Influenzavirus B Infection Drug Sales by Region (2015-2020)
9.2.2 Asia Pacific Influenzavirus B Infection Drug Revenue by Region
9.2.3 China
9.2.4 Japan
9.2.5 South Korea
9.2.6 India
9.2.7 Australia
9.2.8 Taiwan
9.2.9 Indonesia
9.2.10 Thailand
9.2.11 Malaysia
9.2.12 Philippines
9.2.13 Vietnam
10 Latin America
10.1 Latin America Influenzavirus B Infection Drug Market Size YoY Growth 2015-2026
10.2 Latin America Influenzavirus B Infection Drug Market Facts & Figures by Country
10.2.1 Latin America Influenzavirus B Infection Drug Sales by Country
10.2.2 Latin America Influenzavirus B Infection Drug Revenue by Country
10.2.3 Mexico
10.2.4 Brazil
10.2.5 Argentina
11 Middle East and Africa
11.1 Middle East and Africa Influenzavirus B Infection Drug Market Size YoY Growth 2015-2026
11.2 Middle East and Africa Influenzavirus B Infection Drug Market Facts & Figures by Country
11.2.1 Middle East and Africa Influenzavirus B Infection Drug Sales by Country
11.2.2 Middle East and Africa Influenzavirus B Infection Drug Revenue by Country
11.2.3 Turkey
11.2.4 Saudi Arabia
11.2.5 U.A.E
12 Company Profiles
12.1 AbbVie Inc
12.1.1 AbbVie Inc Corporation Information
12.1.2 AbbVie Inc Description and Business Overview
12.1.3 AbbVie Inc Sales, Revenue and Gross Margin (2015-2020)
12.1.4 AbbVie Inc Influenzavirus B Infection Drug Products Offered
12.1.5 AbbVie Inc Recent Development
12.2 Adimmune Corp
12.2.1 Adimmune Corp Corporation Information
12.2.2 Adimmune Corp Description and Business Overview
12.2.3 Adimmune Corp Sales, Revenue and Gross Margin (2015-2020)
12.2.4 Adimmune Corp Influenzavirus B Infection Drug Products Offered
12.2.5 Adimmune Corp Recent Development
12.3 Altravax Inc
12.3.1 Altravax Inc Corporation Information
12.3.2 Altravax Inc Description and Business Overview
12.3.3 Altravax Inc Sales, Revenue and Gross Margin (2015-2020)
12.3.4 Altravax Inc Influenzavirus B Infection Drug Products Offered
12.3.5 Altravax Inc Recent Development
12.4 Amarillo Biosciences Inc
12.4.1 Amarillo Biosciences Inc Corporation Information
12.4.2 Amarillo Biosciences Inc Description and Business Overview
12.4.3 Amarillo Biosciences Inc Sales, Revenue and Gross Margin (2015-2020)
12.4.4 Amarillo Biosciences Inc Influenzavirus B Infection Drug Products Offered
12.4.5 Amarillo Biosciences Inc Recent Development
12.5 Aphios Corp
12.5.1 Aphios Corp Corporation Information
12.5.2 Aphios Corp Description and Business Overview
12.5.3 Aphios Corp Sales, Revenue and Gross Margin (2015-2020)
12.5.4 Aphios Corp Influenzavirus B Infection Drug Products Offered
12.5.5 Aphios Corp Recent Development
12.6 BioCryst Pharmaceuticals Inc
12.6.1 BioCryst Pharmaceuticals Inc Corporation Information
12.6.2 BioCryst Pharmaceuticals Inc Description and Business Overview
12.6.3 BioCryst Pharmaceuticals Inc Sales, Revenue and Gross Margin (2015-2020)
12.6.4 BioCryst Pharmaceuticals Inc Influenzavirus B Infection Drug Products Offered
12.6.5 BioCryst Pharmaceuticals Inc Recent Development
12.7 Cadila Healthcare Ltd
12.7.1 Cadila Healthcare Ltd Corporation Information
12.7.2 Cadila Healthcare Ltd Description and Business Overview
12.7.3 Cadila Healthcare Ltd Sales, Revenue and Gross Margin (2015-2020)
12.7.4 Cadila Healthcare Ltd Influenzavirus B Infection Drug Products Offered
12.7.5 Cadila Healthcare Ltd Recent Development
12.8 ContraFect Corp
12.8.1 ContraFect Corp Corporation Information
12.8.2 ContraFect Corp Description and Business Overview
12.8.3 ContraFect Corp Sales, Revenue and Gross Margin (2015-2020)
12.8.4 ContraFect Corp Influenzavirus B Infection Drug Products Offered
12.8.5 ContraFect Corp Recent Development
12.9 Daiichi Sankyo Company Ltd
12.9.1 Daiichi Sankyo Company Ltd Corporation Information
12.9.2 Daiichi Sankyo Company Ltd Description and Business Overview
12.9.3 Daiichi Sankyo Company Ltd Sales, Revenue and Gross Margin (2015-2020)
12.9.4 Daiichi Sankyo Company Ltd Influenzavirus B Infection Drug Products Offered
12.9.5 Daiichi Sankyo Company Ltd Recent Development
12.10 Fujifilm Holdings Corporation
12.10.1 Fujifilm Holdings Corporation Corporation Information
12.10.2 Fujifilm Holdings Corporation Description and Business Overview
12.10.3 Fujifilm Holdings Corporation Sales, Revenue and Gross Margin (2015-2020)
12.10.4 Fujifilm Holdings Corporation Influenzavirus B Infection Drug Products Offered
12.10.5 Fujifilm Holdings Corporation Recent Development
12.11 AbbVie Inc
12.11.1 AbbVie Inc Corporation Information
12.11.2 AbbVie Inc Description and Business Overview
12.11.3 AbbVie Inc Sales, Revenue and Gross Margin (2015-2020)
12.11.4 AbbVie Inc Influenzavirus B Infection Drug Products Offered
12.11.5 AbbVie Inc Recent Development
12.12 Green Cross Corp
12.12.1 Green Cross Corp Corporation Information
12.12.2 Green Cross Corp Description and Business Overview
12.12.3 Green Cross Corp Sales, Revenue and Gross Margin (2015-2020)
12.12.4 Green Cross Corp Products Offered
12.12.5 Green Cross Corp Recent Development
12.13 Inovio Pharmaceuticals Inc
12.13.1 Inovio Pharmaceuticals Inc Corporation Information
12.13.2 Inovio Pharmaceuticals Inc Description and Business Overview
12.13.3 Inovio Pharmaceuticals Inc Sales, Revenue and Gross Margin (2015-2020)
12.13.4 Inovio Pharmaceuticals Inc Products Offered
12.13.5 Inovio Pharmaceuticals Inc Recent Development
12.14 Kineta Inc
12.14.1 Kineta Inc Corporation Information
12.14.2 Kineta Inc Description and Business Overview
12.14.3 Kineta Inc Sales, Revenue and Gross Margin (2015-2020)
12.14.4 Kineta Inc Products Offered
12.14.5 Kineta Inc Recent Development
12.15 Medicago Inc
12.15.1 Medicago Inc Corporation Information
12.15.2 Medicago Inc Description and Business Overview
12.15.3 Medicago Inc Sales, Revenue and Gross Margin (2015-2020)
12.15.4 Medicago Inc Products Offered
12.15.5 Medicago Inc Recent Development
12.16 MedImmune LLC
12.16.1 MedImmune LLC Corporation Information
12.16.2 MedImmune LLC Description and Business Overview
12.16.3 MedImmune LLC Sales, Revenue and Gross Margin (2015-2020)
12.16.4 MedImmune LLC Products Offered
12.16.5 MedImmune LLC Recent Development
12.17 Mucosis BV
12.17.1 Mucosis BV Corporation Information
12.17.2 Mucosis BV Description and Business Overview
12.17.3 Mucosis BV Sales, Revenue and Gross Margin (2015-2020)
12.17.4 Mucosis BV Products Offered
12.17.5 Mucosis BV Recent Development
12.18 Novavax Inc
12.18.1 Novavax Inc Corporation Information
12.18.2 Novavax Inc Description and Business Overview
12.18.3 Novavax Inc Sales, Revenue and Gross Margin (2015-2020)
12.18.4 Novavax Inc Products Offered
12.18.5 Novavax Inc Recent Development
12.19 Park Active Molecules
12.19.1 Park Active Molecules Corporation Information
12.19.2 Park Active Molecules Description and Business Overview
12.19.3 Park Active Molecules Sales, Revenue and Gross Margin (2015-2020)
12.19.4 Park Active Molecules Products Offered
12.19.5 Park Active Molecules Recent Development
12.20 Romark Laboratories LC
12.20.1 Romark Laboratories LC Corporation Information
12.20.2 Romark Laboratories LC Description and Business Overview
12.20.3 Romark Laboratories LC Sales, Revenue and Gross Margin (2015-2020)
12.20.4 Romark Laboratories LC Products Offered
12.20.5 Romark Laboratories LC Recent Development
12.21 Sanofi
12.21.1 Sanofi Corporation Information
12.21.2 Sanofi Description and Business Overview
12.21.3 Sanofi Sales, Revenue and Gross Margin (2015-2020)
12.21.4 Sanofi Products Offered
12.21.5 Sanofi Recent Development
12.22 Sanofi Pasteur SA
12.22.1 Sanofi Pasteur SA Corporation Information
12.22.2 Sanofi Pasteur SA Description and Business Overview
12.22.3 Sanofi Pasteur SA Sales, Revenue and Gross Margin (2015-2020)
12.22.4 Sanofi Pasteur SA Products Offered
12.22.5 Sanofi Pasteur SA Recent Development
12.23 Shionogi & Co Ltd
12.23.1 Shionogi & Co Ltd Corporation Information
12.23.2 Shionogi & Co Ltd Description and Business Overview
12.23.3 Shionogi & Co Ltd Sales, Revenue and Gross Margin (2015-2020)
12.23.4 Shionogi & Co Ltd Products Offered
12.23.5 Shionogi & Co Ltd Recent Development
12.24 SK Chemicals Co Ltd
12.24.1 SK Chemicals Co Ltd Corporation Information
12.24.2 SK Chemicals Co Ltd Description and Business Overview
12.24.3 SK Chemicals Co Ltd Sales, Revenue and Gross Margin (2015-2020)
12.24.4 SK Chemicals Co Ltd Products Offered
12.24.5 SK Chemicals Co Ltd Recent Development
12.25 TSRL Inc
12.25.1 TSRL Inc Corporation Information
12.25.2 TSRL Inc Description and Business Overview
12.25.3 TSRL Inc Sales, Revenue and Gross Margin (2015-2020)
12.25.4 TSRL Inc Products Offered
12.25.5 TSRL Inc Recent Development
12.26 Vaxart Inc
12.26.1 Vaxart Inc Corporation Information
12.26.2 Vaxart Inc Description and Business Overview
12.26.3 Vaxart Inc Sales, Revenue and Gross Margin (2015-2020)
12.26.4 Vaxart Inc Products Offered
12.26.5 Vaxart Inc Recent Development
12.27 Vectura Group Plc
12.27.1 Vectura Group Plc Corporation Information
12.27.2 Vectura Group Plc Description and Business Overview
12.27.3 Vectura Group Plc Sales, Revenue and Gross Margin (2015-2020)
12.27.4 Vectura Group Plc Products Offered
12.27.5 Vectura Group Plc Recent Development
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Influenzavirus B Infection Drug Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Influenzavirus B Infection Drug Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
List of Figures, Tables and Charts Available in Global and Japan Influenzavirus B Infection Drug Market Insights, Forecast to 2026
List of TablesTable 1. Influenzavirus B Infection Drug Market Segments
Table 2. Ranking of Global Top Influenzavirus B Infection Drug Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Influenzavirus B Infection Drug Market Size Growth Rate by Type 2020-2026 (K Pcs) & (US$ Million)
Table 4. Major Manufacturers of APP-309
Table 5. Major Manufacturers of CF-403
Table 6. Major Manufacturers of GC-3106A
Table 7. Major Manufacturers of KIN-1400
Table 8. Major Manufacturers of Others
Table 9. Global Influenzavirus B Infection Drug Market Size Growth Rate by Application 2020-2026 (K Pcs)
Table 10. Global Influenzavirus B Infection Drug Market Size by Region (K Pcs) & (US$ Million): 2020 VS 2026
Table 11. Global Influenzavirus B Infection Drug Sales by Regions 2015-2020 (K Pcs)
Table 12. Global Influenzavirus B Infection Drug Sales Market Share by Regions (2015-2020)
Table 13. Global Influenzavirus B Infection Drug Revenue by Regions 2015-2020 (US$ Million)
Table 14. Global Influenzavirus B Infection Drug Sales Forecast by Region (2021-2026) (K Pcs)
Table 15. Global Influenzavirus B Infection Drug Sales by Manufacturers (2015-2020) (K Pcs)
Table 16. Global Influenzavirus B Infection Drug Sales Share by Manufacturers (2015-2020)
Table 17. Global Influenzavirus B Infection Drug Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 18. Global Influenzavirus B Infection Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Influenzavirus B Infection Drug as of 2019)
Table 19. Influenzavirus B Infection Drug Revenue by Manufacturers (2015-2020) (US$ Million)
Table 20. Influenzavirus B Infection Drug Revenue Share by Manufacturers (2015-2020)
Table 21. Key Manufacturers Influenzavirus B Infection Drug Price (2015-2020) (USD/Pcs)
Table 22. Influenzavirus B Infection Drug Manufacturers Manufacturing Base Distribution and Headquarters
Table 23. Manufacturers Influenzavirus B Infection Drug Product Type
Table 24. Date of International Manufacturers Enter into Influenzavirus B Infection Drug Market
Table 25. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 26. Global Influenzavirus B Infection Drug Sales by Type (2015-2020) (K Pcs)
Table 27. Global Influenzavirus B Infection Drug Sales Share by Type (2015-2020)
Table 28. Global Influenzavirus B Infection Drug Revenue by Type (2015-2020) (US$ Million)
Table 29. Global Influenzavirus B Infection Drug Revenue Share by Type (2015-2020)
Table 30. Influenzavirus B Infection Drug Average Selling Price (ASP) by Type 2015-2020 (USD/Pcs)
Table 31. Global Influenzavirus B Infection Drug Sales Share by Type (2021-2026)
Table 32. Global Influenzavirus B Infection Drug Sales by Application (2015-2020) (K Pcs)
Table 33. Global Influenzavirus B Infection Drug Sales Share by Application (2015-2020)
Table 34. Global Influenzavirus B Infection Drug Sales Share by Application (2021-2026)
Table 35. Global Influenzavirus B Infection Drug Sales Market Share Forecast by Application (2021-2026)
Table 36. Global Influenzavirus B Infection Drug Revenue by Application (2015-2020) (US$ Million)
Table 37. Global Influenzavirus B Infection Drug Revenue Market Share Forecast by Application (2021-2026)
Table 38. Japan Influenzavirus B Infection Drug Sales (K Pcs) of Key Companies (2015-2020)
Table 39. Japan Influenzavirus B Infection Drug Sales Share by Company (2015-2020)
Table 40. Japan Influenzavirus B Infection Drug Revenue (US$ Million) by Company (2015-2020)
Table 41. Japan Influenzavirus B Infection Drug Sales (K Pcs) by Type (2015-2020)
Table 42. Japan Influenzavirus B Infection Drug Sales Share by Type (2015-2020)
Table 43. Japan Influenzavirus B Infection Drug Revenue (US$ Million) Market Share by Type (2015-2020)
Table 44. Japan Influenzavirus B Infection Drug Price (K Pcs) by Type (2015-2020)
Table 45. Japan Influenzavirus B Infection Drug Sales (K Pcs) by Type (2021-2026)
Table 46. Japan Influenzavirus B Infection Drug Sales Share by Type (2021-2026)
Table 47. Japan Influenzavirus B Infection Drug Revenue (US$ Million) Market Share by Type (2021-2026)
Table 48. Japan Influenzavirus B Infection Drug Revenue Share by Type (2021-2026)
Table 49. Japan Influenzavirus B Infection Drug Price (K Pcs) by Type (2021-2026)
Table 50. Japan Influenzavirus B Infection Drug Sales (K Pcs) by Application (2015-2020)
Table 51. Japan Influenzavirus B Infection Drug Sales Share by Application (2015-2020)
Table 52. Japan Influenzavirus B Infection Drug Revenue (US$ Million) Market Share by Application (2015-2020)
Table 53. Japan Influenzavirus B Infection Drug Sales (K Pcs) by Application (2021-2026)
Table 54. Japan Influenzavirus B Infection Drug Sales Share by Application (2021-2026)
Table 55. Japan Influenzavirus B Infection Drug Revenue (US$ Million) Market Share by Application (2021-2026)
Table 56. Japan Influenzavirus B Infection Drug Revenue Share by Application (2021-2026)
Table 57. North America Influenzavirus B Infection Drug Sales by Country (2015-2020) (K Pcs)
Table 58. North America Influenzavirus B Infection Drug Sales Market Share by Country (2015-2020)
Table 59. North America Influenzavirus B Infection Drug Revenue by Country (2015-2020) (US$ Million)
Table 60. North America Influenzavirus B Infection Drug Revenue Market Share by Country (2015-2020)
Table 61. Europe Influenzavirus B Infection Drug Sales by Country (2015-2020) (K Pcs)
Table 62. Europe Influenzavirus B Infection Drug Sales Market Share by Country (2015-2020)
Table 63. Europe Influenzavirus B Infection Drug Revenue by Country (2015-2020) (US$ Million)
Table 64. Europe Influenzavirus B Infection Drug Revenue Market Share by Country (2015-2020)
Table 65. Asia Pacific Influenzavirus B Infection Drug Sales by Region (2015-2020) (K Pcs)
Table 66. Asia Pacific Influenzavirus B Infection Drug Sales Market Share by Region (2015-2020)
Table 67. Asia Pacific Influenzavirus B Infection Drug Revenue by Region (2015-2020) (US$ Million)
Table 68. Asia Pacific Influenzavirus B Infection Drug Revenue Market Share by Region (2015-2020)
Table 69. Latin America Influenzavirus B Infection Drug Sales by Country (2015-2020) (K Pcs)
Table 70. Latin America Influenzavirus B Infection Drug Sales Market Share by Country (2015-2020)
Table 71. Latin Americaa Influenzavirus B Infection Drug Revenue by Country (2015-2020) (US$ Million)
Table 72. Latin America Influenzavirus B Infection Drug Revenue Market Share by Country (2015-2020)
Table 73. Middle East and Africa Influenzavirus B Infection Drug Sales by Country (2015-2020) (K Pcs)
Table 74. Middle East and Africa Influenzavirus B Infection Drug Sales Market Share by Country (2015-2020)
Table 75. Middle East and Africa Influenzavirus B Infection Drug Revenue by Country (2015-2020) (US$ Million)
Table 76. Middle East and Africa Influenzavirus B Infection Drug Revenue Market Share by Country (2015-2020)
Table 77. AbbVie Inc Corporation Information
Table 78. AbbVie Inc Description and Business Overview
Table 79. AbbVie Inc Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 80. AbbVie Inc Influenzavirus B Infection Drug Product
Table 81. AbbVie Inc Recent Development
Table 82. Adimmune Corp Corporation Information
Table 83. Adimmune Corp Description and Business Overview
Table 84. Adimmune Corp Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 85. Adimmune Corp Product
Table 86. Adimmune Corp Recent Development
Table 87. Altravax Inc Corporation Information
Table 88. Altravax Inc Description and Business Overview
Table 89. Altravax Inc Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 90. Altravax Inc Product
Table 91. Altravax Inc Recent Development
Table 92. Amarillo Biosciences Inc Corporation Information
Table 93. Amarillo Biosciences Inc Description and Business Overview
Table 94. Amarillo Biosciences Inc Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 95. Amarillo Biosciences Inc Product
Table 96. Amarillo Biosciences Inc Recent Development
Table 97. Aphios Corp Corporation Information
Table 98. Aphios Corp Description and Business Overview
Table 99. Aphios Corp Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 100. Aphios Corp Product
Table 101. Aphios Corp Recent Development
Table 102. BioCryst Pharmaceuticals Inc Corporation Information
Table 103. BioCryst Pharmaceuticals Inc Description and Business Overview
Table 104. BioCryst Pharmaceuticals Inc Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 105. BioCryst Pharmaceuticals Inc Product
Table 106. BioCryst Pharmaceuticals Inc Recent Development
Table 107. Cadila Healthcare Ltd Corporation Information
Table 108. Cadila Healthcare Ltd Description and Business Overview
Table 109. Cadila Healthcare Ltd Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 110. Cadila Healthcare Ltd Product
Table 111. Cadila Healthcare Ltd Recent Development
Table 112. ContraFect Corp Corporation Information
Table 113. ContraFect Corp Description and Business Overview
Table 114. ContraFect Corp Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 115. ContraFect Corp Product
Table 116. ContraFect Corp Recent Development
Table 117. Daiichi Sankyo Company Ltd Corporation Information
Table 118. Daiichi Sankyo Company Ltd Description and Business Overview
Table 119. Daiichi Sankyo Company Ltd Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 120. Daiichi Sankyo Company Ltd Product
Table 121. Daiichi Sankyo Company Ltd Recent Development
Table 122. Fujifilm Holdings Corporation Corporation Information
Table 123. Fujifilm Holdings Corporation Description and Business Overview
Table 124. Fujifilm Holdings Corporation Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 125. Fujifilm Holdings Corporation Product
Table 126. Fujifilm Holdings Corporation Recent Development
Table 127. GlaxoSmithKline Plc Corporation Information
Table 128. GlaxoSmithKline Plc Description and Business Overview
Table 129. GlaxoSmithKline Plc Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 130. GlaxoSmithKline Plc Product
Table 131. GlaxoSmithKline Plc Recent Development
Table 132. Green Cross Corp Corporation Information
Table 133. Green Cross Corp Description and Business Overview
Table 134. Green Cross Corp Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 135. Green Cross Corp Product
Table 136. Green Cross Corp Recent Development
Table 137. Inovio Pharmaceuticals Inc Corporation Information
Table 138. Inovio Pharmaceuticals Inc Description and Business Overview
Table 139. Inovio Pharmaceuticals Inc Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 140. Inovio Pharmaceuticals Inc Product
Table 141. Inovio Pharmaceuticals Inc Recent Development
Table 142. Kineta Inc Corporation Information
Table 143. Kineta Inc Description and Business Overview
Table 144. Kineta Inc Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 145. Kineta Inc Product
Table 146. Kineta Inc Recent Development
Table 147. Medicago Inc Corporation Information
Table 148. Medicago Inc Description and Business Overview
Table 149. Medicago Inc Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 150. Medicago Inc Product
Table 151. Medicago Inc Recent Development
Table 152. MedImmune LLC Corporation Information
Table 153. MedImmune LLC Description and Business Overview
Table 154. MedImmune LLC Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 155. MedImmune LLC Product
Table 156. MedImmune LLC Recent Development
Table 157. Mucosis BV Corporation Information
Table 158. Mucosis BV Description and Business Overview
Table 159. Mucosis BV Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 160. Mucosis BV Product
Table 161. Mucosis BV Recent Development
Table 162. Novavax Inc Corporation Information
Table 163. Novavax Inc Description and Business Overview
Table 164. Novavax Inc Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 165. Novavax Inc Product
Table 166. Novavax Inc Recent Development
Table 167. Park Active Molecules Corporation Information
Table 168. Park Active Molecules Description and Business Overview
Table 169. Park Active Molecules Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 170. Park Active Molecules Product
Table 171. Park Active Molecules Recent Development
Table 172. Romark Laboratories LC Corporation Information
Table 173. Romark Laboratories LC Description and Business Overview
Table 174. Romark Laboratories LC Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 175. Romark Laboratories LC Product
Table 176. Romark Laboratories LC Recent Development
Table 177. Sanofi Corporation Information
Table 178. Sanofi Description and Business Overview
Table 179. Sanofi Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 180. Sanofi Product
Table 181. Sanofi Recent Development
Table 182. Sanofi Pasteur SA Corporation Information
Table 183. Sanofi Pasteur SA Description and Business Overview
Table 184. Sanofi Pasteur SA Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 185. Sanofi Pasteur SA Product
Table 186. Sanofi Pasteur SA Recent Development
Table 187. Shionogi & Co Ltd Corporation Information
Table 188. Shionogi & Co Ltd Description and Business Overview
Table 189. Shionogi & Co Ltd Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 190. Shionogi & Co Ltd Product
Table 191. Shionogi & Co Ltd Recent Development
Table 192. SK Chemicals Co Ltd Corporation Information
Table 193. SK Chemicals Co Ltd Description and Business Overview
Table 194. SK Chemicals Co Ltd Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 195. SK Chemicals Co Ltd Product
Table 196. SK Chemicals Co Ltd Recent Development
Table 197. TSRL Inc Corporation Information
Table 198. TSRL Inc Description and Business Overview
Table 199. TSRL Inc Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 200. TSRL Inc Product
Table 201. TSRL Inc Recent Development
Table 202. Vaxart Inc Corporation Information
Table 203. Vaxart Inc Description and Business Overview
Table 204. Vaxart Inc Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 205. Vaxart Inc Product
Table 206. Vaxart Inc Recent Development
Table 207. Vectura Group Plc Corporation Information
Table 208. Vectura Group Plc Description and Business Overview
Table 209. Vectura Group Plc Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 210. Vectura Group Plc Product
Table 211. Vectura Group Plc Recent Development
Table 212. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 213. Key Challenges
Table 214. Market Risks
Table 215. Main Points Interviewed from Key Influenzavirus B Infection Drug Players
Table 216. Influenzavirus B Infection Drug Customers List
Table 217. Influenzavirus B Infection Drug Distributors List
Table 218. Research Programs/Design for This Report
Table 219. Key Data Information from Secondary Sources
Table 220. Key Data Information from Primary Sources
List of Figures
Figure 1. Influenzavirus B Infection Drug Product Picture
Figure 2. Global Influenzavirus B Infection Drug Sales Market Share by Type in 2020 & 2026
Figure 3. APP-309 Product Picture
Figure 4. CF-403 Product Picture
Figure 5. GC-3106A Product Picture
Figure 6. KIN-1400 Product Picture
Figure 7. Others Product Picture
Figure 8. Global Influenzavirus B Infection Drug Sales Market Share by Application in 2020 & 2026
Figure 9. Clinic
Figure 10. Hospital
Figure 11. Others
Figure 12. Influenzavirus B Infection Drug Report Years Considered
Figure 13. Global Influenzavirus B Infection Drug Market Size 2015-2026 (US$ Million)
Figure 14. Global Influenzavirus B Infection Drug Sales 2015-2026 (K Pcs)
Figure 15. Global Influenzavirus B Infection Drug Market Size Market Share by Region: 2020 Versus 2026
Figure 16. Global Influenzavirus B Infection Drug Sales Market Share by Region (2015-2020)
Figure 17. Global Influenzavirus B Infection Drug Sales Market Share by Region in 2019
Figure 18. Global Influenzavirus B Infection Drug Revenue Market Share by Region (2015-2020)
Figure 19. Global Influenzavirus B Infection Drug Revenue Market Share by Region in 2019
Figure 20. Global Influenzavirus B Infection Drug Sales Share by Manufacturer in 2019
Figure 21. The Top 10 and 5 Players Market Share by Influenzavirus B Infection Drug Revenue in 2019
Figure 22. Influenzavirus B Infection Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 23. Global Influenzavirus B Infection Drug Sales Market Share by Type (2015-2020)
Figure 24. Global Influenzavirus B Infection Drug Sales Market Share by Type in 2019
Figure 25. Global Influenzavirus B Infection Drug Revenue Market Share by Type (2015-2020)
Figure 26. Global Influenzavirus B Infection Drug Revenue Market Share by Type in 2019
Figure 27. Global Influenzavirus B Infection Drug Market Share by Price Range (2015-2020)
Figure 28. Global Influenzavirus B Infection Drug Sales Market Share by Application (2015-2020)
Figure 29. Global Influenzavirus B Infection Drug Sales Market Share by Application in 2019
Figure 30. Global Influenzavirus B Infection Drug Revenue Market Share by Application (2015-2020)
Figure 31. Global Influenzavirus B Infection Drug Revenue Market Share by Application in 2019
Figure 32. Japan Influenzavirus B Infection Drug Sales Growth Rate 2015-2026 (K Pcs)
Figure 33. Japan Influenzavirus B Infection Drug Revenue Growth Rate 2015-2026 (US$ Million)
Figure 34. Japan Influenzavirus B Infection Drug Market Share in Global Market 2015-2026
Figure 35. Japan 5 and 10 Largest Influenzavirus B Infection Drug Players Market Share by Revenue in Influenzavirus B Infection Drug in 2019
Figure 36. Japan Influenzavirus B Infection Drug Revenue Share by Type (2015-2020)
Figure 37. Japan Influenzavirus B Infection Drug Revenue Growth Rate by Type in 2015 & 2019
Figure 38. Japan Influenzavirus B Infection Drug Revenue Share by Application (2015-2020)
Figure 39. Japan Influenzavirus B Infection Drug Revenue Growth Rate by Application in 2015 & 2019
Figure 40. North America Influenzavirus B Infection Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 41. North America Influenzavirus B Infection Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 42. North America Influenzavirus B Infection Drug Sales Market Share by Country in 2019
Figure 43. North America Influenzavirus B Infection Drug Revenue Market Share by Country in 2019
Figure 44. U.S. Influenzavirus B Infection Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 45. U.S. Influenzavirus B Infection Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 46. Canada Influenzavirus B Infection Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 47. Canada Influenzavirus B Infection Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 48. Europe Influenzavirus B Infection Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 49. Europe Influenzavirus B Infection Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 50. Europe Influenzavirus B Infection Drug Sales Market Share by Country in 2019
Figure 51. Europe Influenzavirus B Infection Drug Revenue Market Share by Country in 2019
Figure 52. Germany Influenzavirus B Infection Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 53. Germany Influenzavirus B Infection Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 54. France Influenzavirus B Infection Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 55. France Influenzavirus B Infection Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 56. U.K. Influenzavirus B Infection Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 57. U.K. Influenzavirus B Infection Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 58. Italy Influenzavirus B Infection Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 59. Italy Influenzavirus B Infection Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 60. Russia Influenzavirus B Infection Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 61. Russia Influenzavirus B Infection Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 62. Asia Pacific Influenzavirus B Infection Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 63. Asia Pacific Influenzavirus B Infection Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 64. Asia Pacific Influenzavirus B Infection Drug Sales Market Share by Region in 2019
Figure 65. Asia Pacific Influenzavirus B Infection Drug Revenue Market Share by Region in 2019
Figure 66. China Influenzavirus B Infection Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 67. China Influenzavirus B Infection Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 68. Japan Influenzavirus B Infection Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 69. Japan Influenzavirus B Infection Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 70. South Korea Influenzavirus B Infection Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 71. South Korea Influenzavirus B Infection Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 72. India Influenzavirus B Infection Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 73. India Influenzavirus B Infection Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 74. Australia Influenzavirus B Infection Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 75. Australia Influenzavirus B Infection Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 76. Taiwan Influenzavirus B Infection Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 77. Taiwan Influenzavirus B Infection Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 78. Indonesia Influenzavirus B Infection Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 79. Indonesia Influenzavirus B Infection Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 80. Thailand Influenzavirus B Infection Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 81. Thailand Influenzavirus B Infection Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 82. Malaysia Influenzavirus B Infection Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 83. Malaysia Influenzavirus B Infection Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 84. Philippines Influenzavirus B Infection Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 85. Philippines Influenzavirus B Infection Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 86. Vietnam Influenzavirus B Infection Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 87. Vietnam Influenzavirus B Infection Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 88. Latin America Influenzavirus B Infection Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 89. Latin America Influenzavirus B Infection Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 90. Latin America Influenzavirus B Infection Drug Sales Market Share by Country in 2019
Figure 91. Latin America Influenzavirus B Infection Drug Revenue Market Share by Country in 2019
Figure 92. Mexico Influenzavirus B Infection Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 93. Mexico Influenzavirus B Infection Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 94. Brazil Influenzavirus B Infection Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 95. Brazil Influenzavirus B Infection Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 96. Argentina Influenzavirus B Infection Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 97. Argentina Influenzavirus B Infection Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 98. Middle East and Africa Influenzavirus B Infection Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 99. Middle East and Africa Influenzavirus B Infection Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 100. Middle East and Africa Influenzavirus B Infection Drug Sales Market Share by Country in 2019
Figure 101. Middle East and Africa Influenzavirus B Infection Drug Revenue Market Share by Country in 2019
Figure 102. Turkey Influenzavirus B Infection Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 103. Turkey Influenzavirus B Infection Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 104. Saudi Arabia Influenzavirus B Infection Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 105. Saudi Arabia Influenzavirus B Infection Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 106. U.A.E Influenzavirus B Infection Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 107. U.A.E Influenzavirus B Infection Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 108. Porter's Five Forces Analysis
Figure 109. Influenzavirus B Infection Drug Value Chain
Figure 110. Channels of Distribution
Figure 111. Distributors Profiles
Figure 112. Bottom-up and Top-down Approaches for This Report
Figure 113. Data Triangulation
Figure 114. Key Executives Interviewed
Keyplayers in Global and Japan Influenzavirus B Infection Drug Market Insights, Forecast to 2026
AbbVie IncAdimmune Corp
Altravax Inc
Amarillo Biosciences Inc
Aphios Corp
BioCryst Pharmaceuticals Inc
Cadila Healthcare Ltd
ContraFect Corp
Daiichi Sankyo Company Ltd
Fujifilm Holdings Corporation
GlaxoSmithKline Plc
Green Cross Corp
Inovio Pharmaceuticals Inc
Kineta Inc
Medicago Inc
MedImmune LLC
Mucosis BV
Novavax Inc
Park Active Molecules
Romark Laboratories LC
Sanofi
Sanofi Pasteur SA
Shionogi & Co Ltd
SK Chemicals Co Ltd
TSRL Inc
Vaxart Inc
Vectura Group Plc